ARTICLE | Company News
Cypros other research news
June 10, 1996 7:00 AM UTC
CYPR received a $100,000 Phase I SBIR from the National Heart, Lung and Blood Institute to synthesize derivatives of CPC-111. CYPR will develop the prodrugs to enter tissues and then be cleaved by nat...